Brief: Tianjin Development Posts FY Net Profit Attributable Guidance For Tianjin Lisheng Pharmaceutical
23/01/2026 15:26
Jan 23 (Reuters) - Tianjin Lisheng Pharmaceutical Co Ltd 002393.SZ: SEES FY NET PROFIT ATTRIBUTABLE FOR TIANJIN LISHENG PHARMACEUTICAL RMB400 MILLION TO RMB440 MILLION Further company coverage: 002393.SZ ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Tianjin Development Holdings
See all newsHong Kong's Tianjin Development HY revenue on lower pharmaceutical, utilities sales
Brief: Tianjin Development Says Teng Fei Resigns As Chairman And Executive Director
Brief: Tianjin Development Says H1 2026 Net Profit Seen At RMB 73-83 Million For Tianjin Lisheng Pharmaceutical
Brief: Tianjin Development Says Lisheng Pharmaceutical Subscribes To Investment Products Totaling RMB180 Million
Brief: Tianjin Development Says Tianjin Lisheng Pharmaceutical QTRLY Operating Income RMB 332.28 Mln